Hybio Pharmaceutical (300199)

Currency in CNY
24.88
+0.60(+2.47%)
Closed·
300199 Scorecard
Full Analysis
RSI suggests the stock is in overbought territory
300199 is not included in our AI-picked strategies. See which stocks are.
Fair Value
Day's Range
23.9025.28
52 wk Range
8.8327.67
Key Statistics
Bid/Ask
24.88 / 24.88
Prev. Close
24.28
Open
24.24
Day's Range
23.9-25.28
52 wk Range
8.83-27.67
Volume
120.59M
Average Volume (3m)
98.41M
1-Year Change
140.63%
Fair Value
unlockUnlock
Fair Value Upside
unlockUnlock
300199 Scorecardpro icon
Company’s Health
Unlock
Fair Value
Unlock Price
Fair Price
Upside
Analysts Sentiment
Currently not supported.
Members' Sentiments
Bearish
Bullish
ProTips
Short term obligations exceed liquid assets

Technical Analysis

Summary
Strong Sell
Sell
Neutral
Buy
Strong Buy
Strong Buy
Technical Indicators
Strong Buy
Moving Averages
Strong Buy

Hybio Pharmaceutical Company Profile

Hybio Pharmaceutical Co., Ltd. engages in the development, manufacture, and commercialization of therapeutic peptides API and peptide-based drugs in China and internationally. It offers liraglutide, semaglutide, and exenatide for diabetes; terlipressin, desmopressin, and linaclotide for digestive tract and metabolic system; ganirelix, cetrorelix, and atosiban for obstetrics and gynecology; customized peptides; working standards for the peptide APIs and related impurities; peptide CRO; and CDMO services, which include peptide API synthesis and purification process development, finish dosage form development, reference standard preparation and qualification, impurity and product quality study and analysis, GMP system meeting EU and FDA standard, international and Chinese regulatory, and dossier support. The company was founded in 1998 and is based in Wuhan, China.

Employees
1035
Market
China

Compare 300199 to Peers and Sector

Metrics to compare
300199
Peers
Sector
Relationship
P/E Ratio
−240.0x−18.3x−0.5x
PEG Ratio
−2.810.050.00
Price/Book
33.2x3.1x2.6x
Price / LTM Sales
28.7x5.6x3.3x
Upside (Analyst Target)
-−27.1%41.6%
Fair Value Upside
Unlock−11.9%5.9%Unlock

Earnings

Latest Release
May 30, 2025
EPS / Forecast
0.08 / --
Revenue / Forecast
309.97M / --
EPS Revisions
Last 90 days

300199 Income Statement

FAQ

What Stock Exchange Does Hybio Pharmaceutical Trade On?

Hybio Pharmaceutical is listed and trades on the Shenzhen Stock Exchange stock exchange.

What Is the Stock Symbol for Hybio Pharmaceutical?

The stock symbol for Hybio Pharmaceutical is "300199."

What Is the Hybio Pharmaceutical Market Cap?

As of today, Hybio Pharmaceutical market cap is 21.98B.

What Is Hybio Pharmaceutical's Earnings Per Share (TTM)?

The Hybio Pharmaceutical EPS (TTM) is -0.10.

When Is the Next Hybio Pharmaceutical Earnings Date?

Hybio Pharmaceutical will release its next earnings report on 28 Oct 2025.

From a Technical Analysis Perspective, Is 300199 a Buy or Sell?

Based on moving averages and other technical indicators, the daily buy/sell signal is Strong Buy.

How Many Times Has Hybio Pharmaceutical Stock Split?

Hybio Pharmaceutical has split 3 times.

How Many Employees Does Hybio Pharmaceutical Have?

Hybio Pharmaceutical has 1035 employees.

What is the current trading status of Hybio Pharmaceutical (300199)?

As of 13 Aug 2025, Hybio Pharmaceutical (300199) is trading at a price of 24.88, with a previous close of 24.28. The stock has fluctuated within a day range of 23.90 to 25.28, while its 52-week range spans from 8.83 to 27.67.
Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers
© 2007-2025 - Fusion Media Limited. All Rights Reserved.